JNJ-56021927, Prednison acis 5 mg, Tabletten, ZYTIGA 250 mg tablets, placebo to match JNJ-56021927/Apalutamide, -
56021927PCR3001
Phase 3 small_molecule active
Quick answer
JNJ-56021927, Prednison acis 5 mg, Tabletten, ZYTIGA 250 mg tablets, placebo to match JNJ-56021927/Apalutamide, - for Metastatic castration-resistant prostate cancer (mCRPC) is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Metastatic castration-resistant prostate cancer (mCRPC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active